Skip to main content

Evommune, Inc.

corporate_fare Company Profile

Evommune, Inc.

Evommune, Inc. operates as a clinical-stage biotechnology company in the United States. The company develops therapies that target key drivers of chronic inflammatory diseases, with initial clinical development programs focusing on chronic spontaneous urticaria, atopic dermatitis, and ulcerative colitis. Its products include EVO756 for the treatment of CSU and AD; and EVO301 for the treatment of AD and UC. The company was incorporated in 2020 and is based in Palo Alto, California.

Exchange: NYSESector: Life Sciences

show_chartPrice Chart

Loading chart...

feed EVMN - Latest Insights

EVMN
Apr 24, 2026, 4:23 PM EDT
Filing Type: 424B3
Importance Score:
7
EVMN
Apr 21, 2026, 4:05 PM EDT
Filing Type: DEF 14A
Importance Score:
8
EVMN
Apr 13, 2026, 4:09 PM EDT
Filing Type: 8-K
Importance Score:
8
EVMN
Mar 05, 2026, 4:07 PM EST
Filing Type: 10-K
Importance Score:
9
EVMN
Mar 05, 2026, 4:05 PM EST
Filing Type: 8-K
Importance Score:
8
EVMN
Mar 05, 2026, 4:01 PM EST
Source: Dow Jones Newswires
Importance Score:
9
EVMN
Feb 19, 2026, 4:30 PM EST
Filing Type: SCHEDULE 13D/A
Importance Score:
7
EVMN
Feb 17, 2026, 7:28 PM EST
Filing Type: SCHEDULE 13D/A
Importance Score:
7
EVMN
Feb 13, 2026, 8:00 AM EST
Filing Type: 8-K
Importance Score:
8
EVMN
Feb 10, 2026, 8:28 AM EST
Filing Type: 8-K
Importance Score:
9